Abstract Library

#2097 Oral Ondansetron Offers Effective Symptomatic Bridging for Carcinoid Syndrome Refractory to Somatostatin Analogues

Introduction: Somatostatin analogues (SSA) are standard for symptomatic patients with neuroendocrine tumours (NETs). However, most patients experience tachyphylaxis, and limited options exist for this refractory carcinoid syndrome (RCS). Recently, ondansetron has been associated with reduction of bowel movement in a small series.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Kiesewetter B

Authors: Kiesewetter B, Duan H, Haug A, Riss P, Selberherr A,

Keywords: carcinoid syndrome, ondansetron, 5-HT3 antagonist, neuroendocrine tumor, somatostatin, analogues,

#774 The Grading of pNENs in MEN-1 Syndrome: Consequences for Tumor Progression and Surgical Strategy?

Introduction: MEN-1 patients develop multiple pNENs. The treatment of choice ranges from watchful waiting to total pancreatectomy. Up to now, the impact of the grading has not been evaluated to either plan surgery or conservative treatment.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Selberherr A

Authors: Selberherr A, Koperek O, Niederle B,

Keywords: MEN-1, pancreas, pNEN,